Evaluating clinical utility of comprehensive genomic profiling—challenges and opportunities
Practice of cancer precision medicine relies on availability of advanced molecular diagnostic tools to guide use of targeted therapies, which now comprise
Related Articles
Combination extends survival vs. standard first-line therapy for advanced lung cancer
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with…
Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC
Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.
p53 expression in cytology samples may represent a marker of early‐stage cancer
p53 might be useful in discriminating thyroid follicular lesions. p53 is likely to be a useful diagnostic marker in recognizing indeterminate lesions that are well-differentiated…
Coping with Cancer After a Natural Disaster: Frequently Asked Questions for Cancer Patients and Their Caregivers
If you (or a loved one) have cancer and your treatment plan needs to change due to a recent natural disaster, the following questions and…
FDA grants fast track designation for LYT-200 in R/R AML and MDS
On January 9, 2025, the U.S. Food and Drug Administration granted fast track designation for LYT-200, a first-in-class anti-galectin-9 mAb, for the treatment of patients…
Leonard and Norma Klorfine Endowed Chair for Clinical Research awarded to Dr. Geoffrey Hill
Geoffrey Hill, MD, FRACP, FRCPA, was recently announced as the recipient of the Leonard and Norma Klorfine Endowed Chair for Clinical Research at Fred Hutch…
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Nature Cancer – Swanton and colleagues present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of…
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!
VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we…
